Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy

Area of Science:

• Oncology
• Cancer Biology
• Vascular Biology

Background:

• Angiogenesis, the formation of new blood vessels, is a key characteristic of cancer.
• Tumor vessels are often immature and lack pericyte coverage.
• Current anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) signals are clinically used.

Purpose of the Study:

• To evaluate the dual role of anti-angiogenic therapies in cancer treatment.
• To explore vascular normalization as a therapeutic goal.
• To understand the implications of tumor hypoxia and vascular normalization on cancer progression and treatment.

Main Methods:

• Review of current anti-angiogenic drug mechanisms and clinical outcomes.
• Analysis of the effects of transient vascular normalization versus vascular regression on tumor microenvironments.
• Assessment of the impact of tumor hypoxia on cancer cell invasiveness and metastasis.

Main Results:

• Anti-angiogenic drugs transiently normalize tumor vasculature but can ultimately lead to vascular regression.
• Vascular regression induces tumor hypoxia, potentially promoting cancer cell invasion and metastasis.
• Normalized vessels do not cause tumor hypoxia and may improve the efficacy of chemotherapy, radiation, and immunotherapy.

Conclusions:

• Persistent vascular normalization, instead of regression, is a potential alternative therapeutic strategy in anti-angiogenic cancer treatment.
• Targeting sustained vascular normalization could enhance overall anti-cancer treatment effectiveness.
• Understanding the balance between vascular normalization and regression is crucial for optimizing cancer therapy.